The updated World Health Organization program serves the supply of COVID-19 medicines to poor countries, Reuters writes.
According to the publication, the program aims to give poor countries equal access to covid tests, vaccines, and treatments.
Under the ACT-A program, residents of poor countries, particularly those who are mildly infected, will receive a single course of antiviral drugs for $ 10. For comparison, the cost of one course of the drug on the market is $ 700.
According to the publication, we are talking about the drug "Molnupiravir" produced by the American company Merck and its partner Ridgeback Biotherapeutics. The experimental pill may be the first available drug to treat coronavirus.
The American company Merck claims that the anti-COVID-19 pill "Molnupiravir" halves the cases of hospitalization and death in infected people.
Representatives of the company ask the US and other countries to authorize the use of Merck pills.
It should be noted that Molnupiravir is intended for patients who are being treated at home and who have symptoms for less than five days or for those who are in different risk groups.